1. Home
  2. PRCT vs HRMY Comparison

PRCT vs HRMY Comparison

Compare PRCT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$27.73

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$27.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCT
HRMY
Founded
2009
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PRCT
HRMY
Price
$27.73
$27.86
Analyst Decision
Buy
Buy
Analyst Count
11
10
Target Price
$35.44
$46.70
AVG Volume (30 Days)
2.2M
1.2M
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
1.71
7.97
EPS
N/A
2.71
Revenue
$308,054,000.00
$868,453,000.00
Revenue This Year
$32.85
$19.87
Revenue Next Year
$24.66
$12.49
P/E Ratio
N/A
$10.19
Revenue Growth
37.22
21.51
52 Week Low
$19.35
$25.52
52 Week High
$64.89
$40.87

Technical Indicators

Market Signals
Indicator
PRCT
HRMY
Relative Strength Index (RSI) 52.71 32.30
Support Level $19.35 $27.66
Resistance Level $29.24 $30.96
Average True Range (ATR) 2.19 0.92
MACD 0.39 0.12
Stochastic Oscillator 93.42 31.48

Price Performance

Historical Comparison
PRCT
HRMY

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: